GSK’s endometrial cancer regimen of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) has shown promising results in progression-free survival in a phase 3 study.

The trial in adults with primary advanced or recurrent endometrial cancer met its primary endpoint of progression-free survival. Overall survival data is incomplete but shows a favorable trend, the company said.

Jemperli’s U.S. indications are for adults with mismatch repair deficient recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen and for solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

GSK expects to file for approval of the new indication in the first half of 2023.